Evidence map›Paper›PMID 31834924›Full record

ArticlePloS one2019

MicroRNA-710 regulates multiple pathways of carcinogenesis in murine metastatic breast cancer.

Byunghee Yoo, Nikhil Meka, Patrick Sheedy, Ann-Marie Billig, Pamela Pantazopoulos, Zdravka Medarova

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Byunghee YooMGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.ORCID 0000-0001-9066-6399
Nikhil MekaCollege of Arts and Science, New York University, NY, United States of America.
Patrick SheedyDepartment of Health Sciences, CaNCURE Program, Northeastern University, Boston, MA.ORCID 0000-0001-7113-6018
Ann-Marie BilligDepartment of Health Sciences, CaNCURE Program, Northeastern University, Boston, MA.
Pamela PantazopoulosMGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.
Zdravka MedarovaMGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.
Harvard University · USNortheastern University · USNew York University · US

Funding

Therapy for Metastatic breast cancer based on micro RNA silencingR01CA221771 · NCI · MICHIGAN STATE UNIVERSITY · PI MOORE, ANNA · 2018 to 2022
$2.9M
500 MHz NMR Spectrometer for Molecular Imaging ApplicationsS10RR023385 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2007 to 2007
$500k
IVIS Spectrum Imaging SystemS10RR025504 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI MOORE, ANNA · 2009 to 2009
$341k
In vivo methodology for the discovery and validation of miRNA biomarkers in cancer R56CA214464 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MEDAROVA, ZDRAVKA O · 2018 to 2018
$297k
NCI NIH HHS R01 CA221771NCI NIH HHS R56 CA214464NCRR NIH HHS S10 RR023385NCRR NIH HHS S10 RR025504
6 · The paper itself

Abstract

Prior research has shown that critical differences between non-metastatic and metastatic tumor cells are at the level of microRNA. Consequently, harnessing these molecules for the treatment of metastatic cancer could have significant clinical impact. In the present study, we set out to identify metastasis-specific microRNAs which drive metastatic colonization of distant organs. Using a murine model of metastatic breast cancer, we employed a directed approach in which we screened for microRNAs that are differentially expressed between the primary tumors and metastatic lesions but concordantly expressed in all of the metastatic lesions irrespective of the tissue that is colonized. Of the identified targets, we focused on miR-710, which was consistently and significantly downregulated in the metastatic lesions relative to the primary tumors. The level of downregulation was independent of the distant organ that is involved, suggesting that miR-710 plays a fundamental role in metastatic colonization. Computational target prediction suggested a pleiotropic role for miR-710 in apoptosis, migration and invasion, and stemness. Using a previously validated oligonucleotide delivery system, we introduced miR-710 mimics into 4T1 metastatic breast adenocarcinoma cells and assessed the resultant phenotypic effects. We demonstrated significant inhibition of cell viability, migration, and invasion. We also showed that the treatment profoundly enhanced cell senescence, reduced stemness, and influenced markers of epithelial to mesenchymal transition, as evidenced by enhanced E-cadherin and reduced vimentin expression. This knowledge represents a first step towards harnessing a similar approach to discover novel microRNA targets with therapeutic potential in metastasis.

Indexed as

Cell MovementEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticAnimalsApoptosisCarcinogenesisCell ProliferationFemaleMammary Neoplasms, AnimalMiceMice, Inbred BALB CMicroRNAsNeoplasm InvasivenessNeoplasm MetastasisNeoplastic Stem CellsTumor Cells, CulturedMicroRNAsMIRN710 microRNA, mouse

Identifiers

PMID31834924
PMCPMC6910689
OpenAlexW3006698033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.